Tenofovir disoproxil fumarate tablets

A technology of tenofovir fumarate and disoproxil, applied in the field of pharmaceutical preparations, can solve the problems of low resistance of HIV-infected patients, very sensitive to external stimuli, unstable tablet quality, etc., to ensure product stability , the effect of improving disintegration time, good compressibility and capillary properties
CN104644598AInactive Publication Date: 2015-05-27LEPU PHARMACEUTICAL CO LTD
5 Cites 4 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
LEPU PHARMACEUTICAL CO LTD
Publication Date
2015-05-27
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention belongs to the technical field of medicinal preparations, and specifically relates to tenofovir disoproxil fumarate tablets. The tablets comprise tenofovir disoproxil fumarate, a filler, an adhesive, a disintegrating agent, a lubricant and a coating agent; each tablet is 600-800mg and contains 300mg of tenofovir disoproxil fumarate, 25-65% of the filler, 2-5% of the adhesive, 3-15% of the disintegrating agent, 1-3% of the lubricant and 2-3% of the coating agent. The tenofovir disoproxil fumarate tablets have the advantages of low cost and stable product quality.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention belongs to the technical field of pharmaceutical preparations, in particular to a tenofovir disoproxil fumarate tablet. Background technique

[0002] Tenofovir disoproxil fumarate (TDF) is an ester prodrug of tenofovir, which belongs to a new type of nucleotide reverse transcriptase inhibitor, which can inhibit the replication of HIV and HBV viruses. Its main mechanism of action is that it is hydrolyzed to tenofovir after oral administration, and tenofovir is phosphorylated by cellular kinases to generate a pharmacologically active metabolite, tenofovir diphosphate. In 2001 and 2002, tenofovir disoproxil fumarate tablets were approved by the US FDA and the European Union for the treatment of AIDS; in 2008, the European Union and FDA approved it for the treatment of hepatitis B. At present, tenofovir disoproxil fumarate has been marketed in China for the treatment of AIDS, but it has not been approved for the treatment of hepa...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More